Mucormycosis in patients with diabetes mellitus in Russia: registry data analysis

Read full text Summarise with VIRAT
Authors: Sofya N. Khostelidi, S. A. Vartanyan, Artem O. Charushin, A. V. Vagin, O. P. Kozlova, T. S. Bogomolova, Svetlana M. Ignatyeva, Ю Л Авдеенко, Yu. V. Borzova, Nataliya V. Vasilyeva
Cited by: 0
References: 45

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

We observed 100 patients with mucormycosis from 2002 to 2024. We used the EORTC/MSGERC 2019, 2020 criteria for diagnosing mucormycosis. Mucormycosis developed against the background of type 2 diabetes mellitus in 10% of patients, type 1 in 7%, in 83% – after coronavirus infection COVID-19 and glucocorticosteroid therapy. The average glycemia level on the day of diagnosis of mucormycosis was 17 mmol / l. Other risk factors were ketoacidosis – 48%, use of glucocorticosteroids – 85%, lymphocytopenia 44%. The main clinical variant was rhinoorbitocerebral mucormycosis – 93%. Less frequently were mucormycosis of brain (37%), skin (25%), lungs (8%), kidneys (1%). Antifungal therapy was used in 96% of patients: рosaconazole (69%), amphotericin B deoxycholate (59%), lipid forms of amphotericin B (25%), isavuconazole (17%). Surgical treatment used 97%. 12 weeks overall survival was 80%.

Fields of Study & Subjects

Antifungal resistance and susceptibility Infectious Diseases and Mycology Fungal Infections and Studies

Publication details

Journal / source
Journal Infectology
Volume
18
Issue
1
Pages
5–17
Publication date
27 March 2026
Language
EN